254 related articles for article (PubMed ID: 23473641)
21. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients.
Verde Z; Santiago C; Valle B; Fernández-Santander A; Bandrés F; Calvo E; Ruiz JR; Lucía A; Gallego FG
Thromb Haemost; 2009 Mar; 101(3):591-3. PubMed ID: 19277427
[No Abstract] [Full Text] [Related]
23. Creating a genotype-based dosing algorithm for acenocoumarol steady dose.
Cerezo-Manchado JJ; Rosafalco M; Antón AI; Pérez-Andreu V; Garcia-Barberá N; Martinez AB; Corral J; Vicente V; González-Conejero R; Roldán V
Thromb Haemost; 2013 Jan; 109(1):146-53. PubMed ID: 23196355
[TBL] [Abstract][Full Text] [Related]
24. Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism.
Brehm K; Schack J; Heilmann C; Blanke P; Geissler HJ; Beyersdorf F
Eur J Cardiothorac Surg; 2013 Aug; 44(2):309-14; discussion 314-5. PubMed ID: 23423913
[TBL] [Abstract][Full Text] [Related]
25. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations.
Gan GG; Phipps ME; Lee MM; Lu LS; Subramaniam RY; Bee PC; Chang SH
Ann Hematol; 2011 Jun; 90(6):635-41. PubMed ID: 21110192
[TBL] [Abstract][Full Text] [Related]
26. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
[TBL] [Abstract][Full Text] [Related]
27. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.
Verhoef TI; Redekop WK; Buikema MM; Schalekamp T; Van Der Meer FJ; Le Cessie S; Wessels JA; Van Schie RM; De Boer A; Teichert M; Visser LE; Maitland-Van Der Zee AH;
J Thromb Haemost; 2012 Apr; 10(4):606-14. PubMed ID: 22252093
[TBL] [Abstract][Full Text] [Related]
28. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.
van Schie RM; Wessels JA; le Cessie S; de Boer A; Schalekamp T; van der Meer FJ; Verhoef TI; van Meegen E; Rosendaal FR; Maitland-van der Zee AH;
Eur Heart J; 2011 Aug; 32(15):1909-17. PubMed ID: 21636598
[TBL] [Abstract][Full Text] [Related]
29. Effect of CYP2C9, VKORC1, CYP4F2, and GGCX gene variants and patient characteristics on acenocoumarol maintenance dose: Proposal for a dosing algorithm for Moroccan patients.
Elkhazraji A; Bouaiti EA; Boulahyaoui H; Nahmtchougli CP; Zahid H; Bensaid M; Ibrahimi A; Messaoudi N
Drug Discov Ther; 2018; 12(2):68-76. PubMed ID: 29760340
[TBL] [Abstract][Full Text] [Related]
30. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
[TBL] [Abstract][Full Text] [Related]
31. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
32. A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.
Verstuyft C; Delavenne X; Rousseau A; Robert A; Tod M; Diquet B; Lebot M; Jaillon P; Becquemont L
Clin Pharmacokinet; 2012 Jan; 51(1):41-53. PubMed ID: 22149257
[TBL] [Abstract][Full Text] [Related]
33. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
[TBL] [Abstract][Full Text] [Related]
34. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.
Tatarūnas V; Lesauskaitė V; Veikutienė A; Jakuška P; Benetis R
Medicina (Kaunas); 2011; 47(1):25-30. PubMed ID: 21681008
[TBL] [Abstract][Full Text] [Related]
35. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
[TBL] [Abstract][Full Text] [Related]
36. Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects.
Allabi AC; Horsmans Y; Alvarez JC; Bigot A; Verbeeck RK; Yasar U; Gala JL
Eur J Drug Metab Pharmacokinet; 2012 Jun; 37(2):125-32. PubMed ID: 21811894
[TBL] [Abstract][Full Text] [Related]
37. Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population.
Ajmi M; Omezzine A; Achour S; Amor D; Hamdouni H; Ismaïl FBF; Rejeb NB; Kechrid CL; Boughzela E; Bouslama A
Eur J Clin Pharmacol; 2018 Jun; 74(6):711-722. PubMed ID: 29479633
[TBL] [Abstract][Full Text] [Related]
38. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting].
Benusiglio PR; Desmeules J; de Moerloose P; Dayer P
Rev Med Suisse; 2007 Sep; 3(124):2030, 2033-4, 2036. PubMed ID: 17955831
[TBL] [Abstract][Full Text] [Related]
39. A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9.
Rettie AE; Farin FM; Beri NG; Srinouanprachanh SL; Rieder MJ; Thijssen HH
Br J Clin Pharmacol; 2006 Nov; 62(5):617-20. PubMed ID: 16869821
[TBL] [Abstract][Full Text] [Related]
40. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.
Teichert M; van Schaik RH; Hofman A; Uitterlinden AG; de Smet PA; Stricker BH; Visser LE
Clin Pharmacol Ther; 2009 Apr; 85(4):379-86. PubMed ID: 19225451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]